Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Philogen S.p.A.
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy. The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD). The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.
This description comes directly from the study's public registry record.
Jacqueline Mock, PhD · +41 435448804 · regulatory@philogen.com
Federica Bastioli, Pharmaceutical Chemist · +39 057717816 · regulatory@philogen.com
Always discuss trial participation with your own doctor first.
| Universitaetsklinik Hamburg-Eppendorf | Hamburg, Free and Hanseatic City of Hamburg, Germany | Recruiting |
| Universitätsklinikum Heidelberg, Nationalen Centrum für Tumorerkrankungen (NCT), Dermatoonkologie | Heidelberg, Heidelberg, Germany | Recruiting |
| Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie | Leipzig, Leipzig, Germany | Recruiting |
| Universitätsklinikum Tübingen, Klinik für Innere Medizin VIII Medizinische Onkologie und Pneumologie | Tübingen, Germany | Recruiting |
| IEO - Istituto Europeo di Oncologia | Milan, Italy, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria San Luigi Gonzaga | Orbassano, Italy | Not Yet Recruiting |
| Universitätsspital Basel | Basel, Basel, Switzerland | Recruiting |
| Insel Gruppe AG | Bern, Canton of Bern, Switzerland | Recruiting |
| Geneva University Hospital, Oncology Department | Geneva, Canton of Geneva, Switzerland | Recruiting |
| Oncology Institute of Southern Switzerland | Bellinzona, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04471987